Intarcia terminates late-stage diabetes trials

Intarcia Therapeutics Inc. (Boston, Mass.) terminated two late-stage trials evaluating ITCA 650 in Type II diabetes, according to ClinicalTrials.gov. The company received a complete response letter from FDA in September for an NDA seeking approval in the indication (see BioCentury, Oct. 20, 2017).

An Intarcia spokesperson told BioCentury that a "clinical hold was put in place for ongoing marketing studies" and that trial data included in the company's NDA is not related to the terminated studies...